Amyotrophic Lateral Sclerosis (ALS) News and Research

RSS

St. Jude researchers improve brain disease diagnosis with PET imaging and ALS drug

Positron emission tomography (PET) is a nuclear imaging technique used to diagnose conditions such as cancer. An innovative advance from scientists at St. Jude Children's Research Hospital is enhancing the technique's ability to check for signs of neurological disease.

6 Mar 2025

Stress granules as potential biomarkers for neurodegenerative diseases

Stress granules (SGs) are transient organelles that form when cells experience stress, serving as critical hubs for RNA metabolism and cellular survival.

3 Mar 2025

Exploring how 25-hydroxycholesterol triggers ferroptosis in glial cells

Oxysterols are a class of molecules derived from cholesterol via oxidation or as byproducts of cholesterol synthesis.

20 Feb 2025

First insights into familial ALS in Egypt reveal genetic variations and disease progression

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness and eventually death.

18 Feb 2025

Groundbreaking ALS platform trial accelerates research and drug testing

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, has been working with national and international stakeholders to accelerate ALS research by launching the first platform trial in ALS to simultaneously test multiple drugs using shared trial infrastructure and placebo data.

17 Feb 2025

UCLA study reveals key role of mismatch repair genes in Huntington’s disease

A new UCLA Health study has discovered in mouse models that genes associated with repairing mismatched DNA are critical in eliciting damages to neurons that are most vulnerable in Huntington's disease and triggering downstream pathologies and motor impairment, shedding light on disease mechanisms and potential new ways to develop therapies.

11 Feb 2025

Innovative 3D blood-brain barrier model enhances understanding of neuroinflammation

A 3D model accurately mimicking the Blood-Brain Barrier (BBB) in a laboratory environment has been successfully developed by research teams led by Professor Jinah Jang from the Departments of Mechanical Engineering, Life Sciences, IT Convergence Engineering, and the Graduate School of Convergence at POSTECH, and Professor Sun Ha Paek from the Department of Neurosurgery at Seoul National University Hospital.

3 Feb 2025

Review highlights the role of mitochondrial Ca2+ imbalance in neurodegenerative diseases

Mitochondria are crucial organelles for cellular homeostasis, regulating processes such as ATP production, reactive oxygen species (ROS) management and Ca2+ signaling.

24 Jan 2025

Innovative method to study ALS could lead to personalized treatments

Amyotrophic lateral sclerosis (ALS) is a fast-progressing neurodegenerative disease with an average survival time of three years.

19 Dec 2024

Promising ultrasound therapy for Alzheimer's disease licensed to new start-up

A promising ultrasound therapy to potentially restore brain function in people with Alzheimer's disease has been licenced to a new start-up spun out of The University of Queensland.

16 Dec 2024

Researchers develop new approach to effectively deliver therapeutics into the brain

Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach - demonstrated in mouse models and isolated human brain tissue - to safely and effectively deliver therapeutics into the brain, providing new possibilities for treating a wide range of neurological and psychiatric diseases.

25 Nov 2024

Largest ALS patient-based iPSC repository opens new frontiers in research

In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem cell (iPSC) and bio data repository.

15 Nov 2024

Uncovering the pathway behind ALS neurodegeneration

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for Disease Control and Prevention.

8 Nov 2024

Mitochondrial genetics shed light on ALS Risk and protection

Using sequencing techniques, researchers associated 51 mutations in mitochondrial DNA with amyotrophic lateral sclerosis (ALS), an incurable degenerative neurological disorder that leads to muscle atrophy and paralysis.

31 Oct 2024

Defective DNA repair mechanism linked to Huntington's disease progression

Researchers with McMaster University have discovered that the protein mutated in patients with Huntington's Disease doesn't repair DNA as intended, impacting the ability of brain cells to heal themselves.

27 Sep 2024

Innovative ALS study receives $22 million grant for experimental drug

Mayo Clinic in Florida has received a grant from the National Institute of Neurological Disorders and Stroke (NIDS) to begin an innovative study that will provide hundreds of patients with amyotrophic lateral sclerosis (ALS) access to the experimental drug ibudilast over six months.

24 Sep 2024